🧠 This Week in Immunology: FDA Approvals, Groundbreaking Autoimmune Therapies, and Long-Term Psoriasis Results
Stay up to date with the latest developments in immunology—from FDA approvals and cutting-edge autoimmune therapies to breakthrough treatments and acquisitions:
💥 FDA Approves Gamifant for Macrophage Activation Syndrome in Still’s Disease, marking a significant step in controlling hyperinflammation for these rare patients.
🏅 argenx Advances ARGX-119 for Congenital Myasthenic Syndromes, showing proof-of-concept in DOK7-CMS with significant muscle strength improvements in Phase 1b trials.
🤔 iPSC-CAR-NK Therapy from Qihan Biotech shows promise in treating systemic sclerosis, achieving global firsts in iPSC-derived therapies for autoimmune diseases.
💰 AbbVie Acquires Capstan Therapeutics for $2.1B, bringing in innovative CAR-T technology to target B cell-mediated autoimmune diseases like lupus and multiple sclerosis.
💉 Bimekizumab’s 5-Year Efficacy in plaque psoriasis demonstrates sustained responses with minimal adverse events, offering long-term relief for moderate-to-severe patients.
🩺 Apremilast’s Long-Term Benefits in early psoriatic arthritis show sustained improvements in swollen joints and fatigue, offering a new option for early-stage PsA treatment.
🌟 Galderma Launches Trials for Nemolizumab in systemic sclerosis and chronic pruritus, aiming to address severe dermatology needs with targeted IL-31 therapy.
🌸 Roflumilast Cream for atopic dermatitis receives a strong recommendation from the American Academy of Dermatology, expanding into pediatric use with an FDA review expected in 2025.
🧑⚕️ Dupilumab Reduces Lesions in children with atopic dermatitis, showing superior efficacy over methotrexate and cyclosporine in treating moderate-to-severe pediatric AD.
🔬 Rezpegaldesleukin Shows Promise in atopic dermatitis, meeting all primary and secondary endpoints with strong efficacy and fast onset of action in the REZOLVE-AD trial.
💊 EURneffy Adrenaline Nasal Spray launches in Germany, offering a user-friendly, needle-free option for anaphylaxis treatment with improved stability and shelf life.
🥜 DBV Technologies Begins Study on Viaskin Peanut Patch for toddlers with peanut allergies, a pivotal Phase 3 study aiming to revolutionize treatment for young patients.
💉 FDA Reviews SKINVIVE to treat neck lines, a non-surgical option that shows significant improvements in appearance and may soon be available for patients.
📢 Stay Ahead in Immunology Research!
✅ Like, share, and subscribe for weekly updates on immunology and autoimmune innovation
#Immunology #FDAApprovals #AutoimmuneDiseases #PsoriasisTreatment #AtopicDermatitis #Bimekizumab #Dupilumab #ClinicalTrials #HealthcareInnovation #LucidQuest #ImmunologyResearch #PsoriaticArthritis #SKINVIVE #ViaskinPatch